(Total Views: 291)
Posted On: 12/14/2017 12:32:07 PM
Post# of 72446
Cox has a follow up on IPIX B-OM top line results. I strongly suggest that subscribers DO NOT post it in its entirety especially on the other board. Leave the FUDsters in the dark. I can't help but tease them a little though.
"The topline results from the phase 2 trial are now available, and they are very good. Predictably, the market didn’t understand the data, so let’s take a closer look. The market’s ignorance is your opportunity."
"It’s important to realize, however, that pharmaceutical companies have invested massively to get even modest improvements in OM duration. With no effective treatment available, the FDA is extremely likely to approve anything that delivers even marginal relief. The topline P2 data, however, shows that Innovation Pharm’s Brilacidin provides significant reductions in incidence of severe OM."
"The topline results from the phase 2 trial are now available, and they are very good. Predictably, the market didn’t understand the data, so let’s take a closer look. The market’s ignorance is your opportunity."
"It’s important to realize, however, that pharmaceutical companies have invested massively to get even modest improvements in OM duration. With no effective treatment available, the FDA is extremely likely to approve anything that delivers even marginal relief. The topline P2 data, however, shows that Innovation Pharm’s Brilacidin provides significant reductions in incidence of severe OM."
(5)
(0)
